Bharat Parenterals Limited Q4 FY26 results deck summary

Results deck of 18 May 2026, summarised by AI from the filing.

Bharat Parenterals FY26 consolidated revenue ₹345.4 cr; Innoxel revenue ₹72.4 cr (+174%) and FY27 growth guidance issued.

Key takeaways

1. FY26 revenue Consolidated revenue ₹345.4 cr (FY25: ₹340 cr, +1.5%); Q4 FY26 revenue ₹99.6 cr.
2. FY27 guidance BPL standalone FY27 revenue growth 10-15% YoY, EBITDA margin 10-15%; Innoxel 35-45% YoY, 20-25% margin.
3. Innoxel ramp Innoxel FY26 revenue ₹72.4 cr vs ₹26.4 cr FY25 (+174%); Q4 EBITDA-positive.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)